Working… Menu

Intratumoral Cisplatin for Resectable NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04809103
Recruitment Status : Recruiting
First Posted : March 22, 2021
Last Update Posted : March 22, 2021
Johnson & Johnson
Information provided by (Responsible Party):
C. Matthew Kinsey MD, MPH, University of Vermont

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 1, 2023
Estimated Study Completion Date : September 1, 2023